Envista (NYSE:NVST) Stock Rating Reaffirmed by Needham & Company LLC

Envista (NYSE:NVST)‘s stock had its “hold” rating reaffirmed by research analysts at Needham & Company LLC in a research note issued to investors on Thursday, Benzinga reports.

Other equities analysts have also recently issued reports about the stock. UBS Group initiated coverage on shares of Envista in a research note on Friday, January 5th. They set a “neutral” rating and a $26.00 price target for the company. Leerink Partnrs reiterated an “underperform” rating on shares of Envista in a research note on Monday, February 26th. William Blair downgraded shares of Envista from an “outperform” rating to a “market perform” rating in a research note on Thursday, February 8th. Robert W. Baird lowered their target price on Envista from $22.00 to $19.00 and set a “neutral” rating on the stock in a research report on Thursday. Finally, SVB Leerink assumed coverage on Envista in a report on Monday, February 26th. They set an “underperform” rating and a $19.00 target price on the stock. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $25.86.

Envista Stock Down 4.1 %

NVST traded down $0.81 during trading on Thursday, hitting $19.00. The company had a trading volume of 2,239,656 shares, compared to its average volume of 1,979,218. The company has a market capitalization of $3.27 billion, a PE ratio of -26.40, a PEG ratio of 3.83 and a beta of 1.35. The company has a quick ratio of 1.90, a current ratio of 2.27 and a debt-to-equity ratio of 0.34. Envista has a one year low of $18.09 and a one year high of $36.74. The firm’s 50-day moving average price is $20.66 and its 200 day moving average price is $22.53.

Envista (NYSE:NVST) last issued its quarterly earnings results on Wednesday, May 1st. The company reported $0.26 EPS for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.05). The firm had revenue of $623.60 million during the quarter, compared to the consensus estimate of $634.85 million. Envista had a negative net margin of 4.70% and a positive return on equity of 5.84%. The business’s revenue for the quarter was down .6% on a year-over-year basis. During the same quarter last year, the firm earned $0.38 earnings per share. As a group, equities analysts expect that Envista will post 1.38 earnings per share for the current year.

Institutional Investors Weigh In On Envista

A number of large investors have recently added to or reduced their stakes in NVST. Corbyn Investment Management Inc. MD raised its holdings in Envista by 0.6% in the 4th quarter. Corbyn Investment Management Inc. MD now owns 73,899 shares of the company’s stock valued at $1,778,000 after acquiring an additional 462 shares during the period. Alliance Wealth Advisors LLC UT increased its stake in shares of Envista by 6.3% during the third quarter. Alliance Wealth Advisors LLC UT now owns 8,295 shares of the company’s stock worth $231,000 after purchasing an additional 490 shares during the period. Wedge Capital Management L L P NC lifted its holdings in Envista by 0.6% during the 4th quarter. Wedge Capital Management L L P NC now owns 102,309 shares of the company’s stock worth $2,462,000 after purchasing an additional 569 shares during the last quarter. Securian Asset Management Inc. boosted its stake in Envista by 4.3% in the 4th quarter. Securian Asset Management Inc. now owns 14,465 shares of the company’s stock valued at $348,000 after purchasing an additional 590 shares during the period. Finally, Fifth Third Bancorp grew its holdings in Envista by 98.1% in the 4th quarter. Fifth Third Bancorp now owns 1,254 shares of the company’s stock valued at $30,000 after buying an additional 621 shares in the last quarter.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.